1. Home
  2. ARTL vs EZRA Comparison

ARTL vs EZRA Comparison

Compare ARTL & EZRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.75

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo Reliance Global Group Inc. Common Stock

EZRA

Reliance Global Group Inc. Common Stock

N/A

Current Price

$3.89

Market Cap

4.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ARTL
EZRA
Founded
2011
2013
Country
United States
United States
Employees
7
40
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARTL
EZRA
Price
$1.75
$3.89
Analyst Decision
Hold
Analyst Count
2
0
Target Price
N/A
N/A
AVG Volume (30 Days)
163.7K
1.3M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.11
52 Week High
$28.60
$5.45

Technical Indicators

Market Signals
Indicator
ARTL
EZRA
Relative Strength Index (RSI) 36.30 83.14
Support Level $1.62 $0.15
Resistance Level $1.96 N/A
Average True Range (ATR) 0.23 0.32
MACD -0.02 0.39
Stochastic Oscillator 31.32 70.41

Price Performance

Historical Comparison
ARTL
EZRA

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About EZRA Reliance Global Group Inc. Common Stock

Reliance Global Group Inc operates as a holding company that acquires, owns, and actively manages insurance and technology-focused businesses. The company focuses on growing by pursuing acquisition strategies initially, and focuses on wholesale and retail insurance agencies. Its primary move is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations. The Company operates as a single operating segment, the Insurance Segment, earning its revenues from insurance commissions.

Share on Social Networks: